%0 Journal Article
%T 2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Plasmodium falciparum Phosphatidylinositol-4-kinase and Hemozoin Formation with In Vivo Efficacy.
%A Dziwornu GA
%A Seanego D
%A Fienberg S
%A Clements M
%A Ferreira J
%A Sypu VS
%A Samanta S
%A Bhana AD
%A Korkor CM
%A Garnie LF
%A Teixeira N
%A Wicht KJ
%A Taylor D
%A Olckers R
%A Njoroge M
%A Gibhard L
%A Salomane N
%A Wittlin S
%A Mahato R
%A Chakraborty A
%A Sevilleno N
%A Coyle R
%A Lee MCS
%A Godoy LC
%A Pasaje CF
%A Niles JC
%A Reader J
%A van der Watt M
%A Birkholtz LM
%A Bolscher JM
%A de Bruijni MHC
%A Coulson LB
%A Basarab GS
%A Ghorpade SR
%A Chibale K
%J J Med Chem
%V 67
%N 13
%D 2024 Jul 11
%M 38918002
%F 8.039
%R 10.1021/acs.jmedchem.4c01154
%X Structure-activity relationship studies of 2,8-disubstituted-1,5-naphthyridines, previously reported as potent inhibitors of Plasmodium falciparum (Pf) phosphatidylinositol-4-kinase β (PI4K), identified 1,5-naphthyridines with basic groups at 8-position, which retained Plasmodium PI4K inhibitory activity but switched primary mode of action to the host hemoglobin degradation pathway through inhibition of hemozoin formation. These compounds showed minimal off-target inhibitory activity against the human phosphoinositide kinases and MINK1 and MAP4K kinases, which were associated with the teratogenicity and testicular toxicity observed in rats for the PfPI4K inhibitor clinical candidate MMV390048. A representative compound from the series retained activity against field isolates and lab-raised drug-resistant strains of Pf. It was efficacious in the humanized NSG mouse malaria infection model at a single oral dose of 32 mg/kg. This compound was nonteratogenic in the zebrafish embryo model of teratogenicity and has a low predicted human dose, indicating that this series has the potential to deliver a preclinical candidate for malaria.